Heron Therapeutics (HRTX) said Tuesday that the US District Court for the District of Delaware has ruled that claims in two of its Cinvanti injectable emulsion patents are invalid.
The ruling stems from litigation with Azurity Pharmaceuticals and does not affect prior settlements involving Cinvanti or Aponvie, the company said.
Heron said it plans to appeal the decision to the US Court of Appeals for the Federal Circuit and continue defending its intellectual property rights.
Shares of Heron Therapeutics were down more than 15% in premarket activity Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.